Acumen Pharmaceuticals (ABOS) EBT (2020 - 2026)

Acumen Pharmaceuticals has disclosed EBT across 7 years of filings, most recently posting -$32.5 million for Q2 2026.

• In Q2 2026, EBT rose 20.21% year-over-year to -$32.5 million; the TTM figure through Jun 2026 stood at -$104.6 million (up 23.72% YoY), while the FY2025 annual figure was -$120.6 million, down 16.23% from the prior year.
• EBT came in at -$32.5 million for Q2 2026 at Acumen Pharmaceuticals, down from -$21.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$9.1 million in Q1 2022 to a low of -$40.8 million in Q2 2025.
• Average EBT over 5 years is -$20.7 million, with a median of -$18.1 million recorded in 2023.
• Year-over-year, EBT plunged 195.34% in 2022 and soared 33.68% in 2025.
• Over 5 years, EBT stood at -$12.9 million in 2022, then declined by 17.58% to -$15.1 million in 2023, then slumped by 149.02% to -$37.6 million in 2024, then soared by 33.68% to -$25.0 million in 2025, then sank by 30.34% to -$32.5 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$32.5 million in Q2 2026, -$21.2 million in Q1 2026, and -$25.0 million in Q4 2025.